Designed guanidinium-rich amphipathic oligocarbonate molecular transporters complex, deliver and release siRNA in cells

被引:107
作者
Geihe, Erika I. [1 ,2 ]
Cooley, Christina B. [1 ,2 ]
Simon, Jeff R. [1 ]
Kiesewetter, Matthew K. [1 ]
Edward, Justin A. [1 ]
Hickerson, Robyn P. [3 ]
Kaspar, Roger L. [3 ,4 ]
Hedrick, James L. [5 ]
Waymouth, Robert M. [1 ]
Wender, Paul A. [1 ,2 ]
机构
[1] Stanford Univ, Dept Chem, Stanford, CA 94305 USA
[2] Stanford Univ, Dept Chem & Syst Biol, Stanford, CA 94305 USA
[3] TransDerm Inc, Santa Cruz, CA 95060 USA
[4] Stanford Univ, Dept Pediat, Stanford, CA 94305 USA
[5] IBM Corp, Almaden Res Ctr, San Jose, CA 95120 USA
基金
美国国家卫生研究院; 美国国家科学基金会;
关键词
amphipathic co-oligomers; nanoparticles; oligonucleotide delivery; biodegradable oligomers; organocatalysis; RNA-INTERFERENCE; DRUG-DELIVERY; IN-VIVO; PACHYONYCHIA-CONGENITA; BLOCK-COPOLYMERS; GENE-EXPRESSION; THERAPEUTICS; SKIN; CHALLENGES; PROSPECTS;
D O I
10.1073/pnas.1211361109
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The polyanionic nature of oligonucleotides and their enzymatic degradation present challenges for the use of siRNA in research and therapy; among the most notable of these is clinically relevant delivery into cells. To address this problem, we designed and synthesized the first members of a new class of guanidinium-rich amphipathic oligocarbonates that noncovalently complex, deliver, and release siRNA in cells, resulting in robust knockdown of target protein synthesis in vitro as determined using a dual-reporter system. The organocatalytic oligomerization used to synthesize these co-oligomers is step-economical and broadly tunable, affording an exceptionally quick strategy to explore chemical space for optimal siRNA delivery in varied applications. The speed and versatility of this approach and the biodegradability of the designed agents make this an attractive strategy for biological tool development, imaging, diagnostics, and therapeutic applications.
引用
收藏
页码:13171 / 13176
页数:6
相关论文
共 38 条
[1]   RNAi therapeutics: Principles, prospects and challenges [J].
Aagaard, Lars ;
Rossi, John J. .
ADVANCED DRUG DELIVERY REVIEWS, 2007, 59 (2-3) :75-86
[2]   Nonviral delivery of synthetic siRNAs in vivo [J].
Akhtar, Saghir ;
Benter, Ibrahim F. .
JOURNAL OF CLINICAL INVESTIGATION, 2007, 117 (12) :3623-3632
[3]  
Wender Paul A, 2012, Drug Discov Today Technol, V9, pe49, DOI 10.1016/j.ddtec.2011.07.004
[4]   Using drug-excipient interactions for siRNA delivery [J].
Bruno, Katharina .
ADVANCED DRUG DELIVERY REVIEWS, 2011, 63 (13) :1210-1226
[5]   Current progress of siRNA/shRNA therapeutics in clinical trials [J].
Burnett, John C. ;
Rossi, John J. ;
Tiemann, Katrin .
BIOTECHNOLOGY JOURNAL, 2011, 6 (09) :1130-1146
[6]   The promises and pitfalls of RNA-interference-based therapeutics [J].
Castanotto, Daniela ;
Rossi, John J. .
NATURE, 2009, 457 (7228) :426-433
[7]   An insight into the gene delivery mechanism of the arginine peptide system: Role of the peptide/DNA complex size [J].
Choi, Hong Seok ;
Kim, Hyun Hee ;
Yang, Jai Myung ;
Shin, Sungho .
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS, 2006, 1760 (11) :1604-1612
[8]   Oligocarbonate Molecular Transporters: Oligomerization-Based Syntheses and Cell-Penetrating Studies [J].
Cooley, Christina B. ;
Trantow, Brian M. ;
Nederberg, Fredrik ;
Kiesewetter, Matthew K. ;
Hedrick, James L. ;
Waymouth, Robert M. ;
Wender, Paul A. .
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 2009, 131 (45) :16401-+
[9]   Current prospects for RNA interference-based therapies [J].
Davidson, Beverly L. ;
McCray, Paul B., Jr. .
NATURE REVIEWS GENETICS, 2011, 12 (05) :329-340
[10]   The First Targeted Delivery of siRNA in Humans via a Self-Assembling, Cyclodextrin Polymer-Based Nanoparticle: From Concept to Clinic [J].
Davis, Mark E. .
MOLECULAR PHARMACEUTICS, 2009, 6 (03) :659-668